Article

The Muscle-Bone Relationship in X-Linked Hypophosphatemic Rickets.

Shriners Hospital for Children and Department of Pediatrics, McGill University, Montréal, Québec, Canada.
The Journal of Clinical Endocrinology and Metabolism (Impact Factor: 6.31). 03/2013; DOI: 10.1210/jc.2012-4146
Source: PubMed

ABSTRACT Context:We recently found that patients with X-linked hypophosphatemic rickets (XLH) have a muscle function deficit in the lower extremities. As muscle force and bone mass are usually closely related, we hypothesized that patients with XLH could also have a bone mass deficit in the lower extremities.Objective:The study objective was to assess the muscle-bone relationship in the lower extremities of patients with XLH.Setting:The study was carried out in the outpatients department of a pediatric orthopedic hospital.Patients and Other Participants:Thirty individuals with XLH (6 to 60 y; 9 male patients) and 30 age- and gender-matched controls participated.Main Outcome Measures:Calf muscle size and density as well as tibia bone mass and geometry were assessed by peripheral quantitative computed tomography. Muscle function was evaluated as peak force in the multiple 2-legged hopping test.Results:Muscle force was significantly lower in XLH patients than in controls but muscle cross-sectional area did not differ (after adjustment for tibia length). External bone size, expressed as total bone cross-sectional area, was higher in the XLH group than in controls. The XLH cohort also had statistically significantly higher bone mineral content.Conclusions:Patients with XLH have increased bone mass and size at the distal tibia despite muscle function deficits.

0 Bookmarks
 · 
143 Views
  • The Lancet 08/2013; 382(9894):767. · 39.21 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In children, hypophosphatemic rickets is revealed by delayed walking, waddling gait, leg bowing, enlarged cartilages, bone pain, craniostenosis, spontaneous dental abscesses and growth failure. If undiagnosed during childhood, patients with hypophosphatemia present with bone and/or joint pain, fractures, mineralization defects such as osteomalacia, entesopathy, severe dental anomalies, hearing loss and fatigue. Healing rickets is the initial endpoint of treatment in children. Therapy aims at counteracting consequences of FGF23 excess, i.e. oral phosphorus supplementation with multiple daily intakes to compensate for renal phosphate wasting and active vitamin D analogues (alfacalcidol or calcitriol) to counter the 1,25-dioH-vitamin D deficiency. Corrective surgeries for residual leg bowing at the end of growth are occasionally performed. In absence of consensus regarding indications of the treatment in adults, it is generally accepted that medical treatment should be reinitiated (or maintained) in symptomatic patients to reduce pain, which may be due to bone microfractures and/or osteomalacia. In addition to the conventional treatment, optimal care of symptomatic patients requires pharmacological and non-pharmacological management of pain and joint stiffness, through appropriated rehabilitation. Much attention should be given to the dental and periodontal manifestations of hypophosphatemic rickets. Besides vitamin D analogues and phosphate supplements that improve tooth mineralization, rigorous oral hygiene, active endodontic treatment of root abscesses and preventive protection of teeth surfaces are recommended. Current outcomes of this therapy are still not optimal, and therapies targeting the pathophysiology of the disease, i.e. FGF23 excess, are desirable. In this review, medical, dental, surgical and contributions of various expertises to the treatment of hypophosphatemic rickets are described, with an effort to highlight the importance of coordinated care.
    Endocrine connections. 02/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In recent years, as knowledge regarding the etiopathogenetic mechanisms of bone involvement characterizing many diseases has increased and diagnostic techniques evaluating bone health have progressively improved, the problem of low bone mass/quality in children and adolescents has attracted more and more attention, and the body evidence that there are groups of children who may be at risk of osteoporosis has grown. This interest is linked to an increased understanding that a higher peak bone mass (PBM) may be one of the most important determinants affecting the age of onset of osteoporosis in adulthood. This review provides an updated picture of bone pathophysiology and characteristics in children and adolescents with paediatric osteoporosis, taking into account the major causes of primary osteoporosis (PO) and evaluating the major aspects of bone densitometry in these patients. Finally, some options for the treatment of PO will be briefly discussed.
    Italian journal of pediatrics. 06/2014; 40(1):55.

Full-text

Download
67 Downloads
Available from
May 28, 2014